HROW HARROW, INC.
company
SEC Filings & Insider Trading Activity 2026

CIK: 1360214
Health Care
Pharmaceutical Preparations 78 filings
Russell 2000

Latest HARROW, INC. (HROW) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 2, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for HARROW, INC. (HROW) (SEC CIK 1360214), with AI-powered section-by-section summaries updated daily.

10-Q: 54
10-K: 18
8-K: 6

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 2, 2026
10-Q Quarterly Report
Nov 10, 2025
8-K Current Report
Mar 27, 2026

AI 10-K Annual Report Analysis
Latest 10-K (2025-12-31)

Business Overview

  • Core business: U.S. ophthalmic disease management with FDA-approved branded pharmaceuticals and ophthalmology-focused pharmaceutical compounding
  • New product emphasis: Commercial launches planned for BYOOVIZ and BYQLOVI in mid-2026; OPUVIZ expected mid-2027; MELT-300 sedation tablet with FDA NDA filing expected H1 2027
+3 more insights

Risk Factors

  • Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025
  • Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025
+3 more insights

Management Discussion & Analysis

  • Revenue $272.3M up 36% YoY from $199.6M; IHEEZO sales $81.3M (+65% YoY), VEVYE sales $88.7M (+216% YoY), Other branded sales down $12.5M
  • Gross margin branded 81.0% vs 81.3% prior year, ImprimisRx margin 59.9% down from 67.0%, net loss narrowed to $5.1M from $17.5M
+3 more insights

AI 10-Q Quarterly Report Analysis
Latest 10-Q (2025-09-30)

Risk Factors

  • New risk: U.S. government shutdown starting Oct 1, 2025 causing FDA, CMS, SEC staffing cuts, delaying product approvals, reimbursement, and capital access
  • Updated legal risk: Ongoing FDA inspections and warning letters (latest May 2023, 2024), with voluntary recalls and remediation raising compliance scrutiny
Read full Q3 2025 10-Q analysis →

Annual Reports Archive
10-K

AI-powered analysis of HARROW, INC. (HROW) 10-K annual reports filed with SEC EDGAR.

Quarterly Reports Archive
10-Q

AI-powered analysis of HARROW, INC. (HROW) 10-Q quarterly reports filed with SEC EDGAR.

Recent 8-K Filings
Current Reports

AI-powered analysis of HARROW, INC. (HROW) 8-K current reports disclosing material events.

Financial Summary
XBRL

FY2022FY2023FY2024FY2025
Profitability
Revenue$88.6M$130.2M$199.6M$272.3M
Gross Profit$63.2M$90.6M$150.4M$204.4M
Operating Income$431K$8.8M$30.5M
Net Income-$24.4M-$17.5M-$5.1M
Gross Margin71.3%69.6%75.3%75.1%
Op. Margin0.3%4.4%11.2%
Net Margin-18.7%-8.8%-1.9%
Balance Sheet
Total Assets$312.2M$389.0M$399.5M
Equity$70.8M$69.7M$52.4M
ROE-34.5%-25.1%-9.8%

Source: XBRL financial data from HARROW, INC. (HROW) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Mar 27, 2026
8-K
Mar 24, 2026
8-K
Mar 24, 2026
8-K
Mar 10, 2026Analysis
8-K
Mar 2, 2026Analysis
10-K
Mar 2, 2026Dec 31, 2025Analysis
8-K
Feb 2, 2026
10-Q
Nov 10, 2025Sep 30, 2025Analysis
10-Q
Aug 11, 2025Jun 30, 2025
10-Q
May 8, 2025Mar 31, 2025
10-K
Mar 27, 2025Dec 31, 2024
10-Q
Nov 14, 2024Sep 30, 2024
10-Q
Aug 7, 2024Jun 30, 2024
10-Q
May 13, 2024Mar 31, 2024
10-K
Mar 19, 2024Dec 31, 2023
10-Q
Nov 13, 2023Sep 30, 2023
10-Q
Aug 9, 2023Jun 30, 2023
10-Q
May 11, 2023Mar 31, 2023
10-K
Mar 23, 2023Dec 31, 2022
10-Q
Nov 14, 2022Sep 30, 2022
10-Q
Aug 9, 2022Jun 30, 2022
10-Q
May 5, 2022Mar 31, 2022
10-K
Mar 10, 2022Dec 31, 2021
10-Q
Nov 9, 2021Sep 30, 2021
10-Q
Aug 10, 2021Jun 30, 2021

Frequently Asked Questions

What are the latest HROW SEC filings in 2026?

HARROW, INC. (HROW) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HROW file its most recent 10-K annual report?

HARROW, INC. (HROW) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HROW 10-Q quarterly reports?

HARROW, INC. (HROW)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every HROW 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HROW filed recently?

HARROW, INC. (HROW)'s most recent 8-K was filed on March 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HROW insider trading activity (Form 4)?

SignalX aggregates every HROW Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HROW file with the SEC?

HARROW, INC. (HROW) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HROW filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for HARROW, INC. (HROW).

What is HROW's SEC CIK number?

HARROW, INC. (HROW)'s SEC CIK (Central Index Key) number is 1360214. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1360214 to look up all HROW filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HROW return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from HARROW, INC. (HROW) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of HARROW, INC. SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 78+ filings.